BOLT BIOTHERAPEUTICS

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

20 5 2024 12:44:10 提供 NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

17 5 2024 08:47:43 提供 NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

16 5 2024 14:18:13 提供 NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

15 5 2024 09:16:14 提供 NetDania Notify

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

14 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

21 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

27 2 2024 06:00:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

05 12 2023 06:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

30 11 2023 14:03:02 提供 NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

20 11 2023 14:31:57 提供 NetDania Notify

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

09 11 2023 15:05:01 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

07 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

23 10 2023 09:30:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting

18 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

17 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

16 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

28 9 2023 06:00:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

12 9 2023 07:05:25 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics to Participate in September Investor Conferences

05 9 2023 15:15:00 提供 Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 8 2023 15:10:00 提供 Nasdaq GlobeNewswire